CD74 Antibody (LN-2 + CLIP/813), Novus Biologicals™

CD74

0.2mg/mL

Flow Cytometry, Immunohistochemistry (Paraffin), Immunofluorescence

Unconjugated

Mouse

Immunology

10mM PBS and 0.05% BSA with 0.05% Sodium Azide

972

SU-DHL-4 lymphoma cells (LN-2); Recombinant full-length human CD74 protein (CLIP/813)

Primary

Store at 4C.

LN-2 + CLIP/813

Flow Cytometry 0.5 - 1 ug/million cells in 0.1 ml, Immunohistochemistry-Paraffin 1 - 2 ug/ml, Immunofluorescence 1 - 2 ug/ml

Monoclonal

Purified

RUO

Human

CD74 antigen, CD74 antigen (invariant polypeptide of major histocompatibility complex, classII antigen-associated), CD74 molecule, major histocompatibility complex, class II invariant chain, DHLAGgamma chain of class II antigens, HLA class II histocompatibility antigen gamma chain, HLADG, HLA-DR antigens-associated invariant chain, HLA-DR-gamma, Ia antigen-associated invariant chain, Ia-associated invariant chain, Ia-GAMMA, Ii, MHC HLA-DR gamma chain, p33

CD74

IgG

Protein A or G purified

It recognizes a protein of ∼35kDa, identified as CD74. It is a type II transmembrane protein which binds to the peptide binding groove of newly synthesized MHC class II alpha/beta heterodimers and prevents their premature association with endogenous polypeptides. CD74 is expressed primarily by antigen presenting cells, such as B-lymphocytes (from before the pre-B cell stage to before the plasma cell stage), macrophages, and monocytes, and many epithelial cells. Anti-CD74 stains predominantly germinal center lymphocytes and B-cell lymphomas, but rarely T-cell lymphomas. Anti-CD74 has been shown to be useful in differentiating atypical fibroxanthoma (-) from malignant fibrous histiocytoma (+).